Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | The significance of the annual ESMO Breast Cancer meeting

Sung-Bae Kim • 4 May 2022
ESMO Breast 2022
Breast Cancer

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, talks on the excellence of the European Society for Medical Oncology (ESMO) Breast Cancer meetings, providing educational sessions as well as insight into exciting new data. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Sung-Bae Kim

How can we move beyond endocrine therapy in HR+/HER2- breast cancer?
4:44
How can we move beyond endocrine therapy in HR+/HER2- breast cancer?
Sung-Bae Kim • 18 Dec 2025
TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBC
7:05
TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBC
Sung-Bae Kim • 18 Dec 2025
OPTIMAL: oral vs IV paclitaxel in HER2-negative, chemo-naive metastatic breast cancer
2:24
OPTIMAL: oral vs IV paclitaxel in HER2-negative, chemo-naive metastatic breast cancer
Sung-Bae Kim • 30 May 2025
EMBER-3: East Asian subgroup analysis of imlunestrant and abemaciclib
2:37
EMBER-3: East Asian subgroup analysis of imlunestrant and abemaciclib
Sung-Bae Kim • 28 May 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals